NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/28/2024
Back to search
Official data from USPTO
SYNER-G BIOPHARMA GROUP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SYNER-G BIOPHARMA GROUP
ST13
US500000097030514Class
35, 42, 45
Filing
97030514
Registration
7402524
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
05/28/2024
Trademark type
Word
Nice classes
35, 42, 45
Filing date
09/16/2021
Registration date
05/28/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/20/2021
First use in commerce
10/20/2021
Drawing code
4
Owner type
16
Owner location
Framingham, MA, US
Examiner
GAYNOR, BARBARA ANNE
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
SYNER-G BIOPHARMA GROUP LLC
SYNER-G BIOPHARMA GROUP LLC
Syner-G Pharma Consulting, LLC
Representatives
Sara M. Bauer Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 35Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Providing business intelligence services in the fields of pharmaceuticalsbiotechnologylife sciences; business consulting services in the fields of pharmaceuticals and biopharmaceuticals and related technologiesspecificallybusiness consulting with respect to clinical developmentformulationevaluationapprovaldeliverycommercializationmarketinglife-cycle management of drugs; business servicesformulation of best practices for drug discoveryformulation developmentclinical suppliespharmacologytoxicologyclinical suppliesclinical development services; regulatory submission managementassisting others in preparing and filing applications for new pharmaceuticals with governmental regulatory bodies
Class 42
Consulting services in the fields of pharmaceutical research and developmentbiotechnologylife sciences; providing scientific research services in the fields of pharmaceutical design and developmentpharmaceutical chemistrypharmaceutical manufacturing and controls; consulting services regarding research and developmentpharmaceutical drug formulation developmentquality control for others in the fields of pharmaceuticalsbiotechnologylife sciences; technical advisory services in the fields of pharmaceutical research and developmentbiotechnologylife sciences; technical consulting in the fields of pharmaceutical research and developmentbiotechnologylife sciences; technical consulting servicesevaluating the safety of pharmaceutical products in clinical development or in commercial production; consultation services relating to consumer software in the fields of pharmaceuticalsbiotechnologylife sciences; Consulting services for others in the field of designplanningimplementation project management of clinical trial development and clinical trials; Providing technical consulting services in the nature of advising on the testinganalysis and evaluation of the goods of others to determine conformity with certification standards; design and development of computer software for database management in the fields of pharmaceuticalsbiotechnology and life sciences; pharmaceutical drug development services; toxicology services; Scientific research consulting in the field of clinical trial development and clinical trials
Class 45
Regulatory compliance consulting in the fields of pharmaceuticalsbiotechnologylife sciences
Publications
History of USPTO decisions and trademark events.
31 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/24/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/24/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/20/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/20/2024
IUAF
USE AMENDMENT FILED
04/02/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/26/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/26/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/26/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/26/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/26/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/19/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/05/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/03/2023
GNSL
LETTER OF SUSPENSION E-MAILED
01/03/2023
CNSL
SUSPENSION LETTER WRITTEN
01/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/21/2022
GNRT
NON-FINAL ACTION E-MAILED
06/21/2022
CNRT
NON-FINAL ACTION WRITTEN
06/21/2022
DOCK
ASSIGNED TO EXAMINER
06/21/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/21/2021
NWAP
NEW APPLICATION ENTERED
09/20/2021
Continuous trademark protection
Get notified about every new filing that threatens SYNER-G BIOPHARMA GROUP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.